|
000
| 01456nam##2200301za#4500 |
|---|
| 001 | 9.573937 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20210624183936 |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 150406|2000||||xxc|||||o f|0| 0 eng|d |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aH42-2/67-15-1999E-PDF |
|---|
| 110 | 1 |aCanada.|bHealth Canada. |bTherapeutic Products Programme. |
|---|
| 245 | 10|aAddendum to "Dose selection for carcinogenicity studies of pharmaceuticals" : |h[electronic resource]|baddition of a limit dose and related notes |
|---|
| 260 | |aOttawa - Ontario : |bHealth Canada. |cc2000. |
|---|
| 300 | |a8p. |
|---|
| 490 | 1 |aGuidance for industry|vICH topic S1C (R) |
|---|
| 500 | |aThe catalogue number (H42-2/67-15-1999E) and ISBN (0-662-28442-9) for the print edition have been incorrectly copied in this electronic publication. |
|---|
| 590 | |a12-21-Supp|b2012-05-18 |
|---|
| 690 | 07|aTesting|2gcpds |
|---|
| 690 | 07|aCancer|2gcpds |
|---|
| 690 | 07|aDrugs|2gcpds |
|---|
| 690 | 07|aPharmaceutical industry|2gcpds |
|---|
| 775 | 08|tAnnexe à "Sélection des doses pour les études de carcinogénicité de produits pharmaceutiques" : |w(CaOODSP)9.603907 |
|---|
| 776 | 0#|tAddendum to "Dose selection for carcinogenicity studies of pharmaceuticals" : |w(CaOODSP)9.615043 |
|---|
| 830 | #0|aGuidance for industry ;|vICH topic S1C (R)|w(CaOODSP)9.506921 |
|---|
| 856 | 40|ahttp://publications.gc.ca|qPDF|s29 KB|uhttps://publications.gc.ca/collections/Collection/H42-2-67-15-1999E.pdf|yICH topic S1C (R) |
|---|